Kyungdong Pharmaceutical announced that it, together with Aul Bio, has submitted an Investigational New Drug (IND) application to the Korean Ministry of Food and Drug Safety (MFDS) for the phase‑1 clinical trial of AUL009.
AUL009 is a long‑acting injectable formulation of semaglutide, an obesity‑treatment agent, incorporating Aul Bio’s ExTenna™ drug‑delivery platform to enable sustained release.
The new formulation aims to extend the current weekly dosing schedule of semaglutide to a once‑monthly regimen, reducing patient injection burden and enhancing treatment convenience and adherence.
Regulatorische Updates14. Sept. 2026•3 Min. Lesezeit
Kyungdong Pharma, Aul Bio Submit IND for Monthly Long-Acting Semaglutide Injection (AUL009)
Kyungdong Pharmaceutical and Aul Bio have filed an IND with South Korea’s MFDS for phase‑1 testing of AUL009, a monthly long‑acting semaglutide injection using the ExTenna™ platform.
Zusammengestellt vom Pharmacountry-Team · Quelle: KPA News
Themen:
Bewertungen
(0)
(0)
(0)
(0)
(0)
Bewertung hinterlassen